Aravive, Inc. (ARAV)
Stock Price:
$5.95 USD
0.12 (2.06%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $6.11 +0.16 (2.69%) Aug 13, 6:57 PM
Key Info
| Market Cap |
95.31M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-26.31M |
| Shares Out |
16.02M |
| EPS (ttm) |
-1.92 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$5.95 |
| Previous Close |
$5.83 |
| Change ($) |
0.12 |
| Change (%) |
2.06% |
| Day's Open |
5.82 |
| Day's Range |
5.62 - 6.10 |
| Day's Volume |
309,947 |
| 52-Week Range |
3.34 - 15.62 |
More Stats
| Market Cap |
95.31M |
| Enterprise Value |
41.81M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.02M |
| Float |
9.67M |
| EPS (basic) |
-1.92 |
| EPS (diluted) |
-1.92 |
| FCF / Share |
-1.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
883,426 |
| Short Ratio |
4.39 |
| Short % of Float |
7.96% |
| Beta |
3.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.57 |
| Revenue |
n/a |
| Operating Income |
-28.20M |
| Net Income |
-26.31M |
| Free Cash Flow |
-18.57M |
| Net Cash |
53.50M |
| Net Cash / Share |
3.34 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-22.98% |
| ROE |
-46.84% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$27.75*
(366.39% upside)
Low
24.0
Current: $5.95
High
31.0
Target: 27.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 4.75 | 1.37 | 40.00 | - | - | - | - | - |
| Revenue Growth | 246.68% | -96.57% | - | - | - | - | - | - |
| Gross Profit | 4.75 | 1.37 | 40.00 | - | - | - | - | - |
| Operating Income | -21.77 | -75.41 | -84.48 | -96.32 | -82.51 | -46.11 | -19.28 | -12.90 |
| Net Income | -18.22 | -76.33 | -84.98 | -95.82 | -82.18 | -57.51 | -18.50 | -13.22 |
| Shares Outstanding | 11.59 | 7.17 | 5.87 | 5.13 | 4.83 | 3.15 | 0.08 | 0.02 |
| Earnings Per Share | -1.57 | -10.64 | -14.47 | -18.66 | -17.04 | -26.34 | -246.60 | -688.25 |
| Operating Cash Flow | -17.08 | -29.26 | -116 | -40.63 | -69.06 | -39.65 | -17.09 | -11.72 |
| Capital Expenditures | - | -0.03 | -4.30 | -0.09 | - | -0.83 | -0.01 | - |
| Free Cash Flow | -17.08 | -29.29 | -121 | -40.72 | -69.06 | -40.48 | -17.10 | -11.72 |
| Cash & Equivalents | 67.56 | 59.39 | 83.53 | 201 | 182 | 171 | 13.29 | 0.40 |
| Total Debt | 10.23 | - | 5.43 | - | - | - | - | 4.46 |
| Net Cash / Debt | 57.32 | 59.39 | 78.10 | 201 | 182 | 171 | 13.29 | -4.06 |
| Assets | 82.12 | 69.47 | 93.78 | 206 | 185 | 174 | 14.68 | 2.19 |
| Liabilities | 13.07 | 9.53 | 11.02 | 54.50 | 8.83 | 6.93 | 4.48 | 7.28 |
| Book Value | 69.05 | 59.95 | 82.76 | 151 | 177 | 167 | -47.29 | -34.74 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aravive, Inc. |
| Country |
United States |
| Employees |
16 |
| CEO |
Gail Frances McIntyre |
Stock Information
| Ticker Symbol |
ARAV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARAV |
| IPO Date |
March 21, 2014 |
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.